ANHUI ANKE BIOTECHNOLOGY (GROUP) CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.97 CNY | +0.40% |
|
+2.05% | -2.45% |
| Apr. 25 | Anhui Anke Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 28 | Anhui Anke Biotechnology Co., Ltd. Proposes Final Dividend for 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Anhui Anke Biotechnology (Group) Co., Ltd is a China-based company principally engaged in the research, development, manufacture and distribution of biological products, Chinese patent drugs, chemical synthetic drugs, peptide drugs and nucleic acid detection products. The Companyâs main products include recombinant human interferon alfa-2b series, recombinant human growth hormone, peptides Active Pharmaceutical Ingredients (APIs), customized peptides, deoxyribonucleic acid (DNA) fluorescence detection kit, silica beads extraction kit, anti-sperm antibody test kit, pain relieving ointment, amoxicillin granules and capsules, cefaclor dispersible tablets and adefovir dipivoxil tablets, among others. The Company distributes its products in domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-27
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
9.97
CNY
Average target price
19.54
CNY
Spread / Average Target
+95.99%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -2.45% | 2.29B | |
| -4.06% | 86.13B | |
| +1.97% | 39.82B | |
| +56.59% | 25.23B | |
| -13.73% | 15.36B | |
| -8.82% | 11.95B | |
| -15.30% | 11.6B | |
| -41.58% | 11.51B | |
| +6.14% | 8.71B | |
| -7.02% | 8.12B |
- Stock Market
- Equities
- 300009 Stock
- News Anhui Anke Biotechnology (Group) Co., Ltd.
- Anhui Anke Biotechnology Gets Nod to Market Breast Cancer Drug
